3.4.23.B19: plasmepsin V
This is an abbreviated version!
For detailed information about plasmepsin V, go to the full flat file.
Word Map on EC 3.4.23.B19
-
3.4.23.B19
-
plasmepsins
-
plasmodium
-
malaria
-
falciparum
-
erythrocyte
-
pexel
-
antimalarial
-
vacuole
-
aspartyl
-
parasitophorous
-
vivax
-
translocon
-
pepstatin
-
asexual
-
toxoplasma
-
hydroxyethylamine
-
peptidomimetics
-
phosphatidylinositol-3-phosphate
-
cytoadherence
-
exportome
-
picomolar
-
intraerythrocytic
- 3.4.23.B19
-
plasmepsins
- plasmodium
- malaria
- falciparum
- erythrocyte
-
pexel
-
antimalarial
- vacuole
-
aspartyl
-
parasitophorous
- vivax
-
translocon
- pepstatin
-
asexual
- toxoplasma
-
hydroxyethylamine
-
peptidomimetics
- phosphatidylinositol-3-phosphate
-
cytoadherence
-
exportome
-
picomolar
-
intraerythrocytic
Reaction
cleavage of hemoglobin. In contrast to the food vacuole plasmepsins, detergent-solubilized PM V does not bind the aspartic protease inhibitor pepstatin. =
Synonyms
plasmepsin V, Plm V, PlmV, PM V, PMV, PMVm84, PMVp37
ECTree
Advanced search results
Inhibitors
Inhibitors on EC 3.4.23.B19 - plasmepsin V
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
3-(3-hydroxy-1,4-dioxo-1,4-dihydronaphthalen-2-yl)-2,2-dimethylpropyl heptanoate
58.6% residual activity at 0.05 mM
3-(3-hydroxy-1,4-dioxo-1,4-dihydronaphthalen-2-yl)-2,2-dimethylpropyl tridecanoate
49.5% residual activity at 0.05 mM
3-amino-N-[(benzyloxy)carbonyl]-L-phenylalanyl-N-[(3S,4S)-3-hydroxy-6-methyl-1-oxo-1-[(2-phenylethyl)amino]heptan-4-yl]-L-valinamide
-
4-amino-N-[(benzyloxy)carbonyl]-L-phenylalanyl-N-[(3S,4S)-3-hydroxy-6-methyl-1-oxo-1-[(2-phenylethyl)amino]heptan-4-yl]-L-valinamide
-
menisporopsin A
10-30% inhibition at 0.01 mM, 40-60% inhibition at 0.1 mM
N'-benzyl-2-(8-methyl-2,4-dioxo-1,3-diazaspiro[4.5]dec-3-yl)-N'-phenylacetohydrazide
ZINC36767691
N-(2-[[(2-fluorophenyl)methyl]amino]-2-oxoethyl)-2-iodobenzamide
ZINC07922110
N-[(benzyloxy)carbonyl]-3-carbamimidamido-L-phenylalanyl-N-[(3S,4S)-3-hydroxy-6-methyl-1-oxo-1-[(2-phenylethyl)amino]heptan-4-yl]-L-valinamide
-
N-[(benzyloxy)carbonyl]-4-carbamimidamido-L-phenylalanyl-N-[(3S,4S)-3-hydroxy-6-methyl-1-oxo-1-[(2-phenylethyl)amino]heptan-4-yl]-L-valinamide
-
N-[(benzyloxy)carbonyl]-O-carbamimidamido-L-homoseryl-N-[(3S,4S)-3-hydroxy-6-methyl-1-oxo-1-[(2-phenylethyl)amino]heptan-4-yl]-L-valinamide
-
N2-[(benzyloxy)carbonyl]-L-arginyl-N-[(3S,4S)-3-hydroxy-6-methyl-1-oxo-1-[(2-phenylethyl)amino]heptan-4-yl]-L-valinamide
-
N2-[(benzyloxy)carbonyl]-N-carbamimidoyl-L-glutaminyl-N-[(3S,4S)-3-hydroxy-6-methyl-1-oxo-1-[(2-phenylethyl)amino]heptan-4-yl]-L-valinamide
-
N2-[(benzyloxy)carbonyl]-N5-(methylsulfonyl)-L-ornithyl-N-[(3S,4S)-3-hydroxy-6-methyl-1-oxo-1-[(2-phenylethyl)amino]heptan-4-yl]-L-valinamide
-
N2-[(benzyloxy)carbonyl]-N5-(N-cyanocarbamimidoyl)-L-ornithyl-N-[(3S,4S)-3-hydroxy-6-methyl-1-oxo-1-[(2-phenylethyl)amino]heptan-4-yl]-L-valinamide
-
N2-[(benzyloxy)carbonyl]-N5-(N-hydroxycarbamimidoyl)-L-ornithyl-N-[(3S,4S)-3-hydroxy-6-methyl-1-oxo-1-[(2-phenylethyl)amino]heptan-4-yl]-L-valinamide
-
N2-[(benzyloxy)carbonyl]-N5-(N-methoxycarbamimidoyl)-L-ornithyl-N-[(3S,4S)-3-hydroxy-6-methyl-1-oxo-1-[(2-phenylethyl)amino]heptan-4-yl]-L-valinamide
-
N2-[(benzyloxy)carbonyl]-N5-(N-methylcarbamimidoyl)-L-ornithyl-N-[(3S,4S)-3-hydroxy-6-methyl-1-oxo-1-[(2-phenylethyl)amino]heptan-4-yl]-L-valinamide
-
N2-[(benzyloxy)carbonyl]-N5-(N-nitrocarbamimidoyl)-L-ornithyl-N-[(3S,4S)-3-hydroxy-6-methyl-1-oxo-1-[(2-phenylethyl)amino]heptan-4-yl]-L-valinamide
-
N2-[(benzyloxy)carbonyl]-N5-(propan-2-yl)-L-ornithyl-N-[(3S,4S)-3-hydroxy-6-methyl-1-oxo-1-[(2-phenylethyl)amino]heptan-4-yl]-L-valinamide
-
N2-[(benzyloxy)carbonyl]-N5-carbamimidoyl-N5-methyl-L-ornithyl-N-[(3S,4S)-3-hydroxy-6-methyl-1-oxo-1-[(2-phenylethyl)amino]heptan-4-yl]-L-valinamide
-
N2-[(benzyloxy)carbonyl]-N5-carbamoyl-L-ornithyl-N-[(3S,4S)-3-hydroxy-6-methyl-1-oxo-1-[(2-phenylethyl)amino]heptan-4-yl]-L-valinamide
-
N2-[(benzyloxy)carbonyl]-N5-ethanimidoyl-L-ornithyl-N-[(3S,4S)-3-hydroxy-6-methyl-1-oxo-1-[(2-phenylethyl)amino]heptan-4-yl]-L-valinamide
-
N5-acetyl-N2-[(benzyloxy)carbonyl]-L-ornithyl-N-[(3S,4S)-3-hydroxy-6-methyl-1-oxo-1-[(2-phenylethyl)amino]heptan-4-yl]-L-valinamide
-
tert-butyl (3-[[(2-methyl-1H-indol-3-yl)carbonyl]amino]propyl)(pyridin-3-ylmethyl)carbamate
ZINC72012008
nelfinavir
the truncated enzyme PMVm84 exhibits about 53% residual activity at 0.1 mM
the truncated enzyme PMVm84 exhibits about 70% residual activity at 0.1 mM
phenylmethylsulfonyl fluoride
about 20% inhibition at 0.01 mM, 50-70% inhibition at 0.1 mM
-
in contrast to the food vacuole plasmepsins, detergent-solubilized PM V does not bind the aspartic protease inhibitor pepstatin
-
additional information
not influenced by Ca2+; pepstatin A cannot inhibit refolded enzyme activity
-
additional information
-
not influenced by Ca2+; pepstatin A cannot inhibit refolded enzyme activity
-
additional information
the truncated enzyme PMVm84 is not inhibited by pepstatin A
-
additional information
-
the truncated enzyme PMVm84 is not inhibited by pepstatin A
-
additional information
not inhibited by pepstatin A and nelfinavir
-